Practical Management of Dasatinib for Maximum Patient Benefit

Clinical Journal of Oncology Nursing

Volumn 13, Issue 3, 2009, Pages 329-335

  Galinsky, Ilene ^a   Buchanan, Susan ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; DRUG INTERACTION; HUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PYRIMIDINES; THIAZOLES;

EID: 69449088483     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.329-335     Document Type: Review

References (32)

1. Bristol-Myers Squibb. (2006). Dasatinib [Prescribing information]. Princeton, NJ: Author.
2. Chen, Z., Lee, F.Y., Bhalla, K.N., & Wu J. (2006). Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Molecular Pharmacology, 69(5), 1527-1533.
3. Daley, G.Q., Van Etten, R.A., & Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247(4944), 824-830.
4. Donato, N.J., Wu, J., Kong, L.Y., Meng, F., Lee, F., & Talpaz, M. (2005). Constitutive activation of SRC-family kinases in chronic myelogenous leukemia patients resistant to imatinib mesylate in the absence of BCR-ABL mutations: A rationale for use of SRC/ABL dual kinase inhibitor-based therapy [Abstract 1087]. Blood, 106, 316a-317a.
5. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417.
6. Esper, P., Gale, D., & Muehlbauer, P. (2007). What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. Clinical Journal of Oncology Nursing, 11(5), 659-666.
7. Faderl, S., Kantarjian, H.M., Thomas, D.A., Cortes, J., Giles, F., Pierce, S., et al. (2000). Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 36(3-4), 263-273.
8. Gambacorti, C., Cortes, J., Kim, D.W., Dombret, H., Zhu, C., Van Tornout, J.M.A., et al. (2007). Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program [Abstract 472]. Blood, 110, 145a.
9. Guilhot, F., Apperley, J.F., Kim, D.W., Rosti, G., Yuan, X., Van Tornout, J.M.A., et al. (2007). Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005) [Abstract 470]. Blood, 110, 145a.
10. Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J.F., Lipton, J.H., Goldberg, S.L., et al. (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22(6), 1200-1206.
11. Hochhaus, A., Kim, D.W., Rousselot, P., Kantarjian, H.M., Charbonnier, A., Heim, D., et al. (2007). Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: Results from a randomized phase-III trial (CA180034) [Abstract 0359]. Haematologica, 92(Suppl. 1), 128-129.
12. Jabbour, E., Jones, D., Kantarjian, H., O'Brien, S., Garcia-Manero, G., Giles, F., et al. (2006). Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI) [Abstract 750]. Blood, 108, 225a.
13. Jayson, G.C., Parker, G.J., Mullamitha, S., Valle, J.W., Saunders, M., Broughton, L., et al. (2005). Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. Journal of Clinical Oncology, 23(5), 973-981.
14. Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., et al. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood, 109(12), 5143-5150.
15. Kantarjian, H., Rousselot, P., Pasquini, R., Hamerschlak, N., Holowiecki, J., Dejardin, D., et al. (2007). Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017) [Abstract 736]. Blood, 110, 226a.
16. Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., et al. (2007). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110(10), 3540-3546.
17. Kantarjian, H.M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006). New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Annals of Internal Medicine, 145(12), 913-923.
18. Litzow, M.R. (2006). Imatinib resistance: Obstacles and opportunities. Archives of Pathology and Laboratory Medicine, 130(5), 669-679.
19. National Cancer Institute. (2008). Common terminology criteria for adverse events v3.0 (CTCAE). Retrieved June 11, 2008, from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
20. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994-1004.
21. O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., et al. (2005). In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research, 65(11), 4500-4505.
22. Ottmann, O., Hochhaus, A., Saglio, G., Paquette, R., Simonsson, B., Porkka, K., et al. (2007). Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatinib: Updated results from CA180015 (START-L) trial [Abstract 26]. Haematologica, 92(Suppl. 1), 9-10.
23. Ottmann, O.G., & Wassmann, B. (2005). Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology, 1, 118-122.
24. Quintas-Cardama, A., Kantarjian, H.M., Munden, R., Talpaz, M., Bruzzi, J., O'Brien, S., et al. (2006). Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure [Abstract 2164]. Blood, 108, 614a.
25. ®): Clinical features and management, including outcome after hematopoietic growth factor therapy [Abstract 2163]. Blood, 108, 613a-614a.
26. Ramirez, P., & DiPersio, J.F. (2008). Therapy options in imatinib failures. Oncologist, 13(4), 424-434.
27. Sawyers, C.L. (1999). Chronic myeloid leukemia. New England Journal of Medicine, 340(17), 1330-1340.
28. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., & Sawyers, C.L. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305(5682), 399-401.
29. Soverini, S., Martinelli, G., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., et al. (2006). Mutations at residues 315 and 317 in the ABL kinase domain are the main cause of resistance to dasatinib in Philadelphia-positive (Ph+) leukemia patients (pts) [Abstract 836]. Blood, 108, 251a.
30. Stone, R.M., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Hughes, T., Ezzeddine, R., et al. (2007). Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013) [Abstract 734]. Blood, 110, 225a.
31. Surveillance, Epidemiology, and End Results Program. (1973-2006). Limited-use data. Retrieved May 12, 2009, from http://www.seer.cancer.gov
32. Tokarski, J.S., Newitt, J.A., Chang, C.Y., Cheng, J.D., Wittekind, M., Kiefer, S.E., et al. (2006). The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Research, 66(11), 5790-5797.